20Jul/13

Astellas Announces FDA Approval of ASTAGRAF XL™ (tacrolimus extended … – PR Newswire (press release)

Astellas Announces FDA Approval of ASTAGRAF XL™ (tacrolimus extended
PR Newswire (press release)
The two primary, randomized, comparative phase 3 clinical studies to support FDA approval enrolled 1,093 patients (545 on tacrolimus extended-release) in the U.S., Europe, Canada, South America, Australia and South Africa. Astellas was granted

14Jul/13

Federal Circuit Finds Wyeth Restenosis Claims Invalid As Not Enabled – Mondaq News Alerts (registration)

Federal Circuit Finds Wyeth Restenosis Claims Invalid As Not Enabled
Mondaq News Alerts (registration)
As summarized by the Federal Circuit, “[t]he defendants market stent products that elute everolimus and zotarolimus, two drugs that have the same macrocyclic ring as sirolimus but different substituents at the C–42 position.” Wyeth urged a claim

12Jul/13

BOLERO 3: Everolimus may overcome trastuzumab resistance in HER2-positive … – The Oncology Report

BOLERO 3: Everolimus may overcome trastuzumab resistance in HER2-positive
The Oncology Report
CHICAGO – The mTOR inhibitor everolimus appears to be effective at overcoming trastuzumab resistance in patients with advanced HER2-positive breast cancer, based on findings from the BOLERO-3 trial. The 572 patients studied all had locally advanced 

and more »